Fulgent Genetics, Inc.

Informe acción NasdaqGM:FLGT

Capitalización de mercado: US$650.9m

Salud financiera de hoja de balance de Fulgent Genetics

Salud financiera controles de criterios 4/6

Fulgent Genetics tiene un patrimonio de los accionistas total de $1.1B y una deuda total de $1.2M, lo que sitúa su ratio deuda-patrimonio en 0.1%. Sus activos y pasivos totales son $1.2B y $102.0M respectivamente.

Información clave

0.3%

Ratio deuda-patrimonio

US$2.91m

Deuda

Ratio de cobertura de interesesn/a
EfectivoUS$305.70m
PatrimonioUS$1.13b
Total pasivoUS$103.24m
Activos totalesUS$1.23b

Actualizaciones recientes sobre salud financiera

Recent updates

Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

May 10
Shareholders May Be Wary Of Increasing Fulgent Genetics, Inc.'s (NASDAQ:FLGT) CEO Compensation Package

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 07
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04
These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Jan 25
Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy

Jan 09

Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot

Dec 20

I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease

Dec 14
I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($507.8M) de FLGT superan a sus pasivos a corto plazo ($73.0M).

Pasivo a largo plazo: Los activos a corto plazo de FLGT ($386.5M) superan a sus pasivos a largo plazo ($27.3M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: FLGT tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de FLGT ha crecido de 0% a 0.3% en los últimos 5 años.

Cobertura de la deuda: La deuda de FLGT está bien cubierta por el flujo de caja operativo (1451.3%).

Cobertura de intereses: Datos insuficientes para determinar si los pagos de intereses de FLGT sobre su deuda están bien cubiertos por el EBIT.


Hoja de balance


Descubre empresas con salud financiera